Short-course therapy with daily rifapentine in a murine model of latent tuberculosis infection.
about
The role of the novel exopolyphosphatase MT0516 in Mycobacterium tuberculosis drug tolerance and persistenceRifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TBControlling the seedbeds of tuberculosis: diagnosis and treatment of tuberculosis infectionAutoluminescent Mycobacterium tuberculosis for rapid, real-time, non-invasive assessment of drug and vaccine efficacyPotential economic viability of two proposed rifapentine-based regimens for treatment of latent tuberculosis infectionEngineering more stable, selectable marker-free autoluminescent mycobacteria by one stepSimple model for testing drugs against nonreplicating Mycobacterium tuberculosisNovel regimens identified in mice for treatment of latent tuberculosis infection in contacts of patients with multidrug-resistant tuberculosisPopulation pharmacokinetics of rifapentine and desacetyl rifapentine in healthy volunteers: nonlinearities in clearance and bioavailabilityCharacterization of a novel necrotic granuloma model of latent tuberculosis infection and reactivation in mice.Effects of four different meal types on the population pharmacokinetics of single-dose rifapentine in healthy male volunteers.Latent tuberculosis infection: myths, models, and molecular mechanismsrBCG30-induced immunity and cross-protection against Mycobacterium leprae challenge are enhanced by boosting with the Mycobacterium tuberculosis 30-kilodalton antigen 85B.A novel inhibitor of gyrase B is a potent drug candidate for treatment of tuberculosis and nontuberculosis mycobacterial infections.An update on the use of rifapentine for tuberculosis therapy.Short-course chemotherapy with TMC207 and rifapentine in a murine model of latent tuberculosis infection.Current development and future prospects in chemotherapy of tuberculosisRisk of tuberculosis reactivation with tofacitinib (CP-690550).Streptomycin-starved Mycobacterium tuberculosis 18b, a drug discovery tool for latent tuberculosis.Physiologically Based Pharmacokinetic Model of Rifapentine and 25-Desacetyl Rifapentine Disposition in Humans.Mycobacterium tuberculosis multistage antigens confer comprehensive protection against pre- and post-exposure infections by driving Th1-type T cell immunity.Update in tuberculosis 2009.A review of murine models of latent tuberculosis infection.Current management options for latent tuberculosis: a review.Nonclinical models for antituberculosis drug development: a landscape analysis.Animal Models for Tuberculosis in Translational and Precision Medicine.Rifapentine for the treatment of latent tuberculosis.A Multistage Subunit Vaccine Effectively Protects Mice Against Primary Progressive Tuberculosis, Latency and Reactivation.AJRCCM: 100-Year Anniversary. Focus on Tuberculosis.Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB.Treatment of Latent Tuberculosis Infection and Its Clinical Efficacy.
P2860
Q21134950-F2FB9569-1B25-454E-9D24-06E4E8D171F0Q24201325-64EFA861-6643-4194-B0A7-BFC2A44410FFQ28087385-E83BE469-13DA-4F48-BBF8-0F5AE3F2ECCFQ28478840-2CFB0E6D-61D9-4D42-9280-6EB1CB3E6E71Q28479103-4F8F8DDC-4EFD-4274-8111-1BC9D8E15F7DQ28543969-D01A5653-49E7-403A-BF62-3DBF38B59EFBQ30496706-DEA4D91B-CFA6-484A-B9E4-4645973E02C6Q33623003-38ADFA13-075B-46FE-84BE-9CBAA602B256Q33798061-425CDEFC-C283-4187-A9B1-3DA5B716F571Q33826578-040CF8CF-D183-4843-BE5D-BDADD16A75F7Q34045240-EA717E4F-91F0-49F3-A761-302144D3B94FQ34297816-DBD35D37-89CC-4C7A-B84D-354A5292BB92Q34298426-1184FFD5-8018-40D2-8417-FD8714BB326DQ35076966-28BE565B-42F4-4141-A530-FD61A101933BQ35084363-3CD5776C-57A0-43AC-96CB-68AFD9FFB48BQ35527885-BC196EE7-CE76-4AD9-9562-73CDD42D5B3CQ35705874-99A7C0E5-6C67-4425-810F-EB5D77025AEDQ36153907-4AF7A178-6049-4C01-ADF6-C5F342590A6BQ36364079-3FA71E1B-B29E-4321-82E8-DB3D8B107B40Q37120003-57A5F9C0-8BE8-4D2A-912A-9535371D118AQ37665484-A28424F5-9D8D-48DF-8D2F-169F5F0DBDE8Q37704062-7E1B16F4-0294-4B65-AFD3-519EA1B4F272Q37926592-4B83785C-F095-4E19-AC27-76B8DB714BDEQ38066198-60476688-DEF4-4412-865D-8388250A04C2Q38502294-2D0009AB-E56C-48A4-ADE2-1D94883FC048Q38681974-B3350C5B-2841-418F-864D-D44A0C88EF84Q38933165-5BDA41E0-55C9-48BA-B8E6-7E161CA29F5CQ40133620-9D4A0DA6-0644-43C2-B83A-EBBBEB77DD61Q40220575-DF4D0B55-B81C-452D-B607-520E6A6F229EQ41657767-C56F8288-41AD-4DCF-8605-DDD921291E39Q49521299-CB1ACEA0-E1FC-43B0-884C-F21D5F5EEE7D
P2860
Short-course therapy with daily rifapentine in a murine model of latent tuberculosis infection.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 03 September 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Short-course therapy with dail ...... latent tuberculosis infection.
@en
Short-course therapy with dail ...... latent tuberculosis infection.
@nl
type
label
Short-course therapy with dail ...... latent tuberculosis infection.
@en
Short-course therapy with dail ...... latent tuberculosis infection.
@nl
prefLabel
Short-course therapy with dail ...... latent tuberculosis infection.
@en
Short-course therapy with dail ...... latent tuberculosis infection.
@nl
P2093
P2860
P1476
Short-course therapy with dail ...... latent tuberculosis infection.
@en
P2093
Eric L Nuermberger
Ian M Rosenthal
Jacques H Grosset
Ming Zhang
Tianyu Zhang
P2860
P304
P356
10.1164/RCCM.200905-0795OC
P407
P577
2009-09-03T00:00:00Z